Moderna’s COVID-19 vaccine candidate is expected for emergency use by December.
Stéphane Bancel, the Chief Executive Officer of Moderna said earlier this week that the United States government could approve its vaccine for emergency use in December of this year. He added that this depends on the type of results they receive back from its ongoing clinical trials which are expected by the end of November.
Moderna began its massive clinical study with 30,000 participants in July. Moderna’s vaccine is one of only a handful of projects worldwide that have reached Phase 3 trials. Some vaccines produced in Russia and China have already been approved for early or limited use in their respective nations, but none have completed Phase 3 trials yet.
Ultimovacs shares recent obtained positive results from Phase I Trial Evaluating Universal Cancer Vaccine in Non-Small Cell Lung Cancer
Ultimovacs recently announced the five-year overall survival data from the Phase I trial evaluating Universal Cancer Vaccine, UV1 as maintenance therapy for patients with non-small cell lung cancer. The positive results confirm the safety and tolerability and indicate encouraging initial signals of long-term survival benefit.
During the study, a total of 18 non-small cell lung cancer patients whose disease had not progressed after receiving at least 2nd line treatment with chemotherapy were enrolled to receive UV1 monotherapy as a maintenance treatment. The results of the study included the safety and tolerability of UV1 as well as initial signs of clinical response.
Ultimovacs also presented 48-months of follow-up data at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting last year.
Britain partners with Oxford Immunotec to assess COVID-19 vaccine T-cell responses
Britain recently announced its partnership with an Oxford-based firm to provide testing for the T-cell response of coronavirus vaccine candidates to try to assess their immune responses.
The UK Vaccine Taskforce selected Oxford Immunotec to supply T-cell testing for its assessment of different vaccine candidates.
T-cell immunity is said to be essential to protect against infection from the SARS-COV-2 virus and could provide longer-term immunity than antibodies.
Britain has signed supply deals for six different coronavirus vaccine candidates, including those being made by AstraZeneca and Pfizer, and BioNTech and would need Oxford Immunotec’s technology platform to measure the T-cell response in a standardized way.